+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mesenchymal Stem Cells (MSC): Global Strategic Business Report

  • PDF Icon

    Report

  • 202 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 2769226

Global Mesenchymal Stem Cells (MSC) Market to Reach $9.5 Billion by 2030

The global market for Mesenchymal Stem Cells (MSC) estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2022-2030. Bone Marrow, one of the segments analyzed in the report, is projected to record 13.5% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Adipose Tissues segment is readjusted to a revised 15.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 11.4% CAGR

The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10% and 9.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Select Competitors (Total 56 Featured) -

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Mesenchymal Stem Cells (MSC)

What is the estimated value of the Global Market for Mesenchymal Stem Cells (MSC)?

The Global Market for Mesenchymal Stem Cells (MSC) was estimated to be valued at $3 Billion in 2020.

What is the growth rate of the Global Market for Mesenchymal Stem Cells (MSC)?

The growth rate of the Global Market for Mesenchymal Stem Cells (MSC) is 11.7%, with an estimated value of $6.5 Billion by 2027.

What is the forecasted size of the Global Market for Mesenchymal Stem Cells (MSC)?

The Global Market for Mesenchymal Stem Cells (MSC) is estimated to be worth $6.5 Billion by 2027.

Who are the key companies in the Global Market for Mesenchymal Stem Cells (MSC)?

Key companies in the Global Market for Mesenchymal Stem Cells (MSC) include Cell Applications Inc., Celprogen Inc., Cyagen US Inc., Genlantis Inc., Lonza Group, Mesoblast Limited, MilliporeSigma, Neuromics, Orthofix International N.V. and PromoCell GmbH.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Mesenchymal Stem Cells Market on a Rapid Growth Path
  • Recent Market Activity
  • Current and Future Analysis
  • The Present and Future of MSC Therapies
  • Select MSC-based Therapeutics
  • Mesenchymal Stem Cell Research
  • Completed Phase III Studies with MSCs
  • MSCs are Being Explored for Several New Treatment Possibilities
  • Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
  • Software Companies Endeavour to Cash in on the Boom
  • Mesenchymal Stem Cells (MSC) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • Cell Applications, Inc. (USA)
  • Celprogen, Inc. (USA)
  • Cyagen US Inc. (USA)
  • Genlantis, Inc. (USA)
  • Lonza Group (Switzerland)
  • Mesoblast Limited (Australia)
  • MilliporeSigma (USA)
  • Neuromics (USA)
  • Orthofix International N.V. (Italy)
  • PromoCell GmbH (Germany)
  • R&D Systems, Inc. (USA)
  • ScienCell Research Laboratories (USA)
  • Stemcell Technologies Inc. (Canada)
  • Stemedica Cell Technologies, Inc. (USA)
  • Thermo Fischer Scientific, Inc. (USA)
  • Vitro Biopharma (USA)
3. MARKET TRENDS & DRIVERS
  • Development of Regenerative Medicine Accelerates Demand for MSCs
  • Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
  • Global Aging Population Statistics - Opportunity Indicators
  • Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
  • Key Disease Statistics - Opportunity Indicators
  • Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market
  • Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
  • Adult Stem Cells and Embryonic Stem Cells - A Comparison
  • MSCs Versus Embryonic or Induced Pluripotent Stem Cells
  • MSC Therapies - Immune to Ethical Issues Applicable to Embryonic Stem Cells
  • MSCs - A Potential Vehicle for 'Targeted Drug Delivery'
  • Stem Cell Based Bone Grafts: Promising Growth Ahead
  • Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
  • Major Challenges Confronting Mesenchymal Stem Cell Market
  • Allogeneic MSCs - Offering Promise in Immunosuppressive and Tissue Repair Therapy
  • Administration Route Determines the Effectiveness of MSCs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Adipose Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Fetal Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 21: World 16-Year Perspective for Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 24: World 16-Year Perspective for Other Sources of MSC Isolation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 27: World 16-Year Perspective for Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 28: World Recent Past, Current & Future Analysis for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 29: World Historic Review for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 30: World 16-Year Perspective for Drug Development & Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 31: World Recent Past, Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 32: World Historic Review for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 33: World 16-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 34: World Recent Past, Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 35: World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 36: World 16-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 37: World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 38: World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 39: World 16-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 40: World Mesenchymal Stem Cells (MSC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.